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The human mitochondrial genome encodes RNA components of its own translational machinery to produce the 13 mitochondrial-
encoded subunits of the respiratory chain. Nuclear-encoded gene products are essential for all processes within the organelle, including
RNA processing. Transcription of the mitochondrial genome generates large polycistronic transcripts punctuated by the 22 mitochon-
drial (mt) tRNAs that are conventionally cleaved by the RNase P-complex and the RNase Z activity of ELAC2 at 50 and 30 ends, respec-
tively.We report the identification ofmutations in ELAC2 in five individuals with infantile hypertrophic cardiomyopathy and complex I
deficiency. We observed accumulated mtRNA precursors in affected individuals muscle and fibroblasts. Although mature mt-tRNA,
mt-mRNA, and mt-rRNA levels were not decreased in fibroblasts, the processing defect was associated with impaired mitochondrial
translation. Complementation experiments in mutant cell lines restored RNA processing and a yeast model provided additional
evidence for the disease-causal role of defective ELAC2, thereby linking mtRNA processing to human disease.Introduction
Human mitochondria house the four mitochondrial respi-
ratory chain complexes to produce ATP through oxidative
phosphorylation (OXPHOS). In addition to mitochondrial
mRNAs (mt-mRNAs) coding for the OXPHOS subunits,
mtDNA codes for the RNA components (22 mt-tRNAs
and 2 mt-rRNAs) required for mitochondrial translation.
The remaining factors involved in mitochondrial protein
synthesis are nuclear encoded and need to be imported
into the organelle. Among these nuclear components,
more than 20 are linked to heritable disorders, including
mitochondrial ribosomal subunits, aminoacyl-tRNA syn-
thetases, tRNA-modifying enzymes, translation elongation
factors, and two auxiliary proteins.1,2 Human mt-mRNAs,
mt-tRNAs, and mt-rRNAs are not transcribed in their
mature form but are part of large polycistronic heavy (H)
strand and light (L) strand precursor transcripts generated
from the 16.6 kb mitochondrial genome. Because the
mitochondrial genes are frequently adjacent to or sepa-
rated by only a few noncoding nucleotides (or even
overlap in ATPase 8/6 and ND4L/ND4), processing of the
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. Open access utantly produce mt-mRNAs and mt-rRNAs.3,4 Endonucleo-
lytic cleavage at the 50 and 30 termini of the tRNAs in
mitochondria relies on the RNase P complex and the
RNase Z activity of ELAC2, respectively. There are two
human genes encoding orthologs of the bacterial RNase
Z (elaC): ELAC1 (MIM 608079) and ELAC2 (elaC homolog
1 and 2). ELAC1 codes for a short form of RNase Z that is
localized in the cytosol,5 whereas ELAC2 (MIM 605367)
encodes a long form of RNase Z. In contrast to the short
RNase Z found in diverse organisms, ELAC2-encoded
long RNase Z is restricted to eukaryotes. Alternative trans-
lation initiation of ELAC2 generates two products, of
which only the longer form localizes to mitochondria.5
In HeLa cells, ELAC2 silencing led to increased levels of
30 end unprocessed mt-tRNA precursors.6,7 However, no
effects on mitochondrial translation or respiration have
been observed.7
We performed exome sequencing in two unrelated indi-
viduals with infantile hypertrophic cardiomyopathy, lactic
acidosis, and isolated complex I deficiency (MIM 252010)
in skeletal muscle, and we discovered pathogenic muta-
tions in ELAC2. Subsequent screening of additional
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ELAC2 missense mutation in two affected siblings in a
third family, for a total of four disease alleles. Fibroblasts
from these individuals had elevated levels of 30 end
unprocessed mt-tRNA levels, and we observed impaired
mitochondrial translation in a mutant cell line.
Despite previous siRNA-knockdown studies in HeLa cells
suggesting that ELAC2 is not crucial for mitochondrial
respiration and translation,7 we show here that this
protein is necessary for efficient mitochondrial protein
synthesis and OXPHOS function.Subjects and Methods
Subjects
Written informed consent was obtained from all individuals
investigated or their guardians, and the ethics committee of the
Technische Universita¨t Mu¨nchen approved the study. Genetic,
biochemical, and clinical findings of individuals with ELAC2
mutations are summarized in Table 1. Pedigrees of investigated
families are shown in Figure 1A.
Individual #61525 (II-2, c.[631C>T; 1559C>T], p.[Arg211*;
Thr520Ile]), a boy, was the second child of healthy, unrelated
parents from Germany (family F1 in Figure 1A). An older sister is
healthy; a younger brother (#57415; II-3) is similarly affected. He
was born at term but reduced fetal growth was noticed during the
last 4 weeks of pregnancy and his birth weight was 2,690 g. After
initially normal development, a failure to thrive was noticed at
the age of 4 months. A severe hypertrophic cardiomyopathy and
elevated serum lactate concentrations (5.7 mmol/l, normal range
[n.r.] < 2.2 mmol/l) were noticed. A metabolic workup showed
slightly elevated orotic acid in urine (12.7 mmol/mol creatinine,
n.r.< 2mmol/mol creatinine) and elevated alanine and glutamine
in serum. Acylcarnitine profiles in serum were unremarkable, and
so was screening for lysosomal storage disorders including Pompe
disease and CDG syndromes. A myocardial biopsy showed severe
myocardial damage with necrosis and enlarged mitochondria
with abnormal cristae in electron microscopy.
At the age of 6 months, this boy died because of acute cardiac
decompensation associatedwith severe lactic acidosis (16mmol/l).
Post mortem mutation screening of SCO2 (MIM 604272) and for
disease mutations in the mtDNA were normal.
His younger brother, individual #57415 (family F1: II-3 in
Figure 1A, c.[631C>T; 559C>T], p.[Arg211*; Thr520Ile]), was
born at term after normal pregnancy with a birth weight of
3,140 g. Development was unremarkable until the age of 3months
when, similar to his brother, a mild muscular hypotonia was
noted. Further clinical features were dysphagia, retarded growth,
and microcephaly (<3rd percentile). ECG showed signs of left
ventricular hypertrophy and paroxysmal supraventricular extra-
systoles and an echocardiography revealed a left ventricular
hypertrophy without outflow tract obstruction. ProBNP was
increased (1,336 pg/ml, n.r. < 100 pg/ml). Neuroimaging showed
mild hyperintensities in T2-weighted MRI in the pallida and the
brainstem without diffusion abnormalities. EEG was normal.
Brainstem evoked response audiometry demonstrated moderate
central hearing impairment. He had a mild, compensated meta-
bolic acidosis and elevated blood lactate levels (3.8–5.7 mmol/l,
n.r.< 2.2 mmol/l). Plasma amino acid analysis indicated increased
alanine (682 mmol/l, n.r. 165–373 mmol/l) and glutamine
(789 mmol/l, n.r. 32–129 mmol/l) levels, which were normal in a212 The American Journal of Human Genetics 93, 211–223, August 8repeated analysis. Urinary organic acid analysis showed elevated
2-oxoglutarate, 3-hydroxyadipinlactone, 4-hydroxyphenyllactate,
and ethylmalonic acid. Orotic acid was increased (11.5 mmol/mol
creatinine). Lightmicroscopy of skeletal muscle showed unspecific
myopathic features with mitochondria of increased size and
abnormal cristae structure in electron microscopy. Mitochondrial
functional analysis in fresh muscle showed a decreased oxidation
of pyruvate/malate, pyruvate/malate/ADP, and malate/pyruvate/
malonate and a deficiency of respiratory chain complex I in frozen
muscle.
The boy was treated with propranolol and captopril, a fat-
rich diet (60 percent of total calories) was started, and he
was substituted with coenzyme Q10 (10 mg/kg body weight),
riboflavin (10 mg/kg), thiamine (10 mg/kg), and L-carnitine
(15 mg/kg). During the subsequent 12 months, his cardiac
function stabilized and hypertrophy slightly decreased. His
psychomotor development continued to progress but is still not
adequate with a status of approximately 10 months by the age of
24 months.
Individual #61982 (II-5, c.[460T>C; 460T>C], p.[Phe154Leu;
Phe154Leu]), a girl, was the fifth child born to first-degree cousin
parents of Arabic descent (family F2 in Figure 1A). Family history
was remarkable for two previous first-trimester miscarriages and
two elder sibling deaths. Her brother died at 13 days of unknown
cause and her sister at 3 months resulting from cardiac failure
from dilation of hypertrophic cardiomyopathy. Only rudimentary
investigations were performed, which showed increased plasma
lactate and ammonia.
The baby was born at 36 weeks weighing only 1,300 g. She was
screened with echocardiography, which was normal. At her
2 month review, she had developed cardiomyopathy and growth
continued to falter. Muscle tone appeared normal and there were
no dysmorphic features. Cardiac function was stabilizedmedically
and she was transferred to a metabolic center. Plasma lactates at
the time of good cardiac compensation ranged from 5.4 to
8.1 mmol/l (n.r. 0.7–2.2 mmol/l).
Metabolic screening including blood film for vacuolated
lymphocytes, white cell and plasma lysosomal cardiomyopathy
screen, urinary glycosaminoglycans, transferrin isoelectric focus-
ing, urine organic acids, and acylcarnitine profile was normal.
Plasma amino acids showed only raised alanine in keeping with
lactic acidosis.
Parents initially refused muscle and skin biopsies. The child
deteriorated severely at 11 months of age with fulminant cardio-
genic shock. She developed multiorgan failure complicated by
candidal sepsis and died 20 days later.
Muscle biopsy taken during her final illness showed no major
histopathological changes—oxidative enzyme activities including
succinate dehydrogenase and cytochrome c oxidase (COX)
were normal. Modified Gomori trichrome staining did not reveal
ragged-red fibers. Respiratory chain enzyme studies revealed
evidence of isolated complex I deficiency (60% of lowest control
value); all other complex activities were normal.
Individual #36355 (II-1, c.[1267C>T; 1267C>T], p.[Leu423Phe;
Leu423Phe]), a girl, was the first child of healthy first-degree
cousins from Turkey (family F3 in Figure 1A). A younger sister
(#65937, II-2) is also affected. Born at term, her birth weight,
length, and head circumference were on the 10th percentile. At
the age of 5 months, she first presented with two short episodes
of convulsion without fever. An echocardiography performed
because of a cardiac murmur revealed a left ventricular hyper-
trophic cardiomyopathy. She had muscular hypotonia and her, 2013
Table 1. Genetic, Biochemical, and Clinical Findings in Individuals with ELAC2 Mutations
ID Sex
OXPHOS Activities and RNA Processing
ELAC2 Mutations
RCC
% of
Lowest
Control
Absolute
Values
Reference
Range
Mean x-Fold Accumulation of
Unprocessed RNA Intermediates Clinical Features
cDNA (NM_018127.6)
and Protein
(NP_060597) Muscle Fibroblasts AO Course HCM Other Features
#61525a male c.[631C>T; 1559C>T],
p.[Arg211*;
Thr520Ile]
NA NA NA 4 months death at
6 months
yes intrauterine growth retardation,
lactic acidosis, myocardial
damage and necrosis associated
with acute cardiac failure
#57415a,b male c.[631C>T; 1559C>T],
p.[Arg211*; Thr520Ile]
I
II
IIþIII
IV
50%
normal
normal
normal
0.07
0.29
0.46
1.07
(0.14–0.35)
(0.18–0.41)
(0.30–0.67)
(0.91–2.24)
167 10.6 3 months alive at 2 years,
10 months
yes psychomotor and growth
retardation, muscular hypotonia,
microcephaly, dysphagia, lactic
acidosis, sensorineural hearing
impairment, hyperintensities
in basal ganglia at age 3 months
#61982b female c.[460T>C; 460T>C],
p.[Phe154Leu;
Phe154Leu]
I
II
IIþIII
IV
60%
ND
normal
normal
0.062
ND
0.085
0.021
(0.104–0.268)
ND
(0.040–0.204)
(0.014–0.034)
NA 10.5 2 months death at
11 months
yes intrauterine growth retardation,
lactic acidosis, cardiac failure,
normal muscle biopsy findings
#36355a female c.[1267C>T; 1267C>T],
p.[Leu423Phe;
Leu423Phe]
I
II
IIþIII
IV
82%
ND
100%
78%
0.14
ND
0.08
0.70
(0.17–0.56)
ND
(0.08–0.45)
(0.90–4.70)
NA NA 5 months alive at
13 years
yes mild psychomotor delay,
muscular hypotonia
#65937a female c.[1267C>T; 1267C>T],
p.[Leu423Phe;
Leu423Phe]
I
II
IIþIII
IV
86%
100%
normal
normal
0.12
0.18
0.32
1.61
(0.14–0.35)
(0.18–0.41)
(0.30–0.67)
(0.91–2.24)
30 2.6 5 months death at 4 years,
9 months
yes later
DCM
psychomotor retardation,
muscular hypotonia, cardiac
failure, COX-deficient fibers
Mitochondrial respiratory chain complexes (RCC) in muscle: I, NADH-CoQ-oxidoreductase; II, succinate dehydrogenase; IIþIII, succinate cytochrome c oxidoreductase; IV/COX, cytochrome c oxidase. Enzyme activities were
determined in muscle biopsies and normalized to citrate synthase (CS). Absolute values and reference ranges are given in [mU/mU CS]. Abbreviations are as follows: AO, age of onset; HCM, hypertrophic cardiomyopathy;
DCM, dilated cardiomyopathy; NA, no material available; ND, not determined.
aThese individuals are siblings.
bInvestigated by exome sequencing.
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Figure 1. ELAC2 Mutation Status and Gene Structure
(A) Pedigrees of three families with mutations in ELAC2. Individual #57415 (F1: II-3) from unrelated parents was found to have a com-
pound heterozygous mutation. Individuals #61982 (F2: II-5) and #65937 (F3: II-2) born to consanguineous parents (first-degree cousins)
carry homozygous missense mutations in ELAC2.
(B) Gene structure of ELAC2with known protein domains of the gene product and localization and conservation of amino acid residues
affected by mutations. Intronic regions are not drawn to scale.statomotor development was delayed. Metabolic work-up was
unremarkable despite slightly elevated lactate levels. Respiratory
chain enzyme analysis in frozen skeletal muscle indicated reduced
activities of complexes I and IV.
Over the next years a mild but constant developmental delay
was documented, with sitting at the age of 18 months, first steps
at the age of 24 months, and first words at the age of 30 months.
A brain MRI performed at the age of 20 months was normal.
She is now 13 years old and attends a school for mentally
handicapped children. The cardiac situation remained stable
under a treatment with enalapril and carvedilol. The last echocar-
diography at the age of 13 years showed a concentric hypertrophy
and a dilatation of the left ventricle (left ventricular diameter
49 mm, ventricular septum thickness 7 mm, posterior wall
thickness 8 mm, fraction of shortening 22%).214 The American Journal of Human Genetics 93, 211–223, August 8The younger sister of individual #36355 (F3: II-1), subject
#65937 (F3: II-2 in Figure 1A, c.[1267C>T; 1267C>T],
p.[Leu423Phe; Leu423Phe]), was born at term after a normal preg-
nancy. At birth, her weight was 3,790 g, length 51 cm, and head
circumference 36 cm, and she had an APGAR score of 9/10/10.
Initial growth and psychomotor development were normal but
a concentric left ventricular hypertrophy was observed at the
age of 5 months. Her growth parameters were all on the 25th
percentile at the age of 9 months. However, she showed muscular
hypotonia, reduced head control, and a delay of motor develop-
ment of approximately 5 months.
Testing of respiratory chain enzymes in a skeletal muscle biopsy
taken at the age of 11 months revealed deficiencies in complexes
I and IV without signs of a mitochondrial disorder in histology
and histochemistry., 2013
Her psychomotor development continued to be retarded. She
started to walk at the age of 36 months and spoke two words at
the age of 48 months. A treatment with furosemid, enalapril,
and carvedilol failed to prevent progression of the hypertrophic
cardiomyopathy to a dilated cardiomyopathy documented at the
age of 4 years and 2 months together with a left ventricular frac-
tion of shortening of 22%, a ventricular septum thickness of
8 mm, and a right bundle branch block. Clinically, she showed
signs of a severe cardiac failure including arterial hypotonia (65/
33 mm Hg) and renal failure resulting from reduced perfusion.
Analysis of a second skeletal muscle biopsy confirmed previous
biochemical findings, but numerous COX-negative fibers were
now observed.
This girl died at the age of 4 years and 9 months from cardiac
failure despite intense anticongestive therapy and treatment
with coenzyme Q10 and riboflavin.Exome Sequencing and Variant Prioritization
We performed exome sequencing in individuals #57415 (F1: II-3)
and #61982 (F2: II-5) with the SureSelect Human All Exon 50 Mb
kit (Agilent) for in-solution enrichment of exonic regions followed
by sequencing as 100 base-pair (bp) paired-end runs on a
HiSeq2000 (Illumina).8 For sequencing statistics see Table S1
available online. Read alignment to the human genome (UCSC
Genome Browser build hg19) was done with Burrows-Wheeler
Aligner (BWA, v.0.5.8) and single-nucleotide variants and
small insertions and deletions were detected with BWA and
SAMtools (version 0.1.7). Given that OXPHOS disorders are rare,
we excluded variants with a frequency >0.2% in 1,846 control
exomes and public databases. Based on a recessive model of inher-
itance, we next searched for genes carrying predicted homozygous
or compound heterozygous nonsynonymous variants followed
by a filter for genes encoding proteins with a mitochondrial
localization according to a MitoP2 score > 0.5.9Heteroduplex Analysis
To screen for genetic variation in ELAC2, we performed a high-
resolution melting curve analysis (HRMA) in 350 individuals pre-
senting with clinical and biochemical features suggestive of a
mitochondrial disorder. Sample preparation for subsequent anal-
ysis on a LightScanner instrument (Idaho Technology) was done
as described previously.10 In brief, primers were designed to cover
all 24 coding exons of ELAC2. Primer sequences and PCR protocols
are available upon request. Double-strand DNA binding LCGreen
Plus dye (Idaho Technology) was added to the mastermix prior to
PCR. The PCR products were then covered with a layer of mineral
oil before starting HRMA.qPCR of mt-tRNAs
To verify that ELAC2 mutations impair RNase Z activity, we
analyzed levels of 30 unprocessedmt-tRNAs by qPCR. Total cellular
RNA was isolated from fibroblasts of individuals #57415 (F1: II-3),
#61982 (F2: II-5), and #65937 (F3: II-2) as well as from skeletal
muscle of individuals #57415 and #65937. After DNase treatment
(TurboDNase, Ambion), RNAwas reverse transcribedwith random
hexamer primers (Maxima RT, Thermo Scientific) and used for
subsequent qPCR analysis. PCR reactions were set up with B-R
SYBR Green SuperMix for iQ (Quanta Biosciences), covered with
a layer of mineral oil, and performed in an iCycler iQ5 (BioRad
Laboratories). Oligonucleotides were designed to flank RNA pro-
cessing sites between tRNAs and their adjacent mRNAs or rRNAs,The Amerwith one primer binding within and one primer complementary
to the region downstream of the tRNA gene. Sequences of the
primers used are given in Table S2. Cycle threshold (Ct) values
were normalized to the mean of two housekeeping genes, HPRT1
and RPL27.RNA-Seq of the Mitochondrial Transcriptome
The quality of the RNA isolated from whole-cell lysates was deter-
mined with the Agilent 2100 BioAnalyzer (RNA 6000 Nano Kit,
Agilent). All samples had a RNA integrity number (RIN) value
greater than 8. For library preparation, 1 mg of total RNA per sam-
ple was used. RNA molecules were poly(A) selected, fragmented,
and reverse transcribed with the Elute, Prime, Fragment Mix
(EPF, Illumina). End repair, A-tailing, adaptor ligation, and library
enrichment were performed as described in the Low Throughput
protocol of the TruSeq RNA Sample Prep Guide (Illumina). RNA
libraries were assessed for quality and quantity with the Agilent
2100 BioAnalyzer and the Quant-iT PicoGreen dsDNA Assay Kit
(Life Technologies). RNA libraries were sequenced as 100 bp
paired-end runs on an Illumina HiSeq2000 platform. On average
we produced about 8.4 GB of sequence per sample. With BWA
(v.0.6.1) we were able tomap about 75% of the reads to the human
reference genome (UCSC Genome Browser build hg19). Duplicate
reads were removed. For comparison, the relative coverage was
calculated separately for each sample by dividing the coverage at
each position by the number of reads mapped to mtDNA multi-
plied by 1 Mio (average number of mapped reads was 0.85 Mio
over all samples).Lentiviral Transduction
In order to prove the pathogenicity of newly identified missense
alleles, we expressed the wild-type ELAC2 cDNA in fibroblasts of
individuals #57415 (F1: II-3), #61982 (F2: II-5), and #65937 (F3:
II-2) by using the p.Lenti6.3/V5-TOPO vector system (Invitrogen)
according to the manufacturer’s protocol. In brief, HEK293 FTcells
cultured in 9 cm diameter dishes were cotransfected with both
600 ng pLenti6.3/V5-TOPO plasmid containing ELAC2 wild-type
cDNA and 9 mg ViraPower Lentiviral Packaging Mix. After
changing medium 24 hr after transfection, viruses were produced
for 72 hr. Virus-containing supernatant was collected, centrifuged,
diluted 1:2 in fresh medium, and used to infect the fibroblast
cell lines to be transduced. At 1 day after infection, virus con-
taining supernatant was replaced with fresh medium. At 2 days
after infection, selection of transduced cells was started with
blasticidin-containing medium (c ¼ 3.6 mg/ml).11Mitochondrial Translation Assays
Metabolic labeling of mitochondrial proteins with [35S]methio-
nine was performed essentially as described previously.2 In
brief, fibroblasts derived from individual #57415 (F1: II-3) were
incubated in methionine/cysteine-free medium supplemented
with 2 mM L-glutamine, 48 mg/ml cysteine, 50 mg/ml uridine,
and 100 mg/ml emetine dihydrochloride to block cytosolic protein
synthesis. Cells were incubated for 10 min before addition of
120 mCi/ml of [35S]methionine. Labeling was performed for
30 min and the cells were washed twice with standard growth
medium. Equal amounts of total cell lysates were separated by
SDS-PAGE and newly synthesized proteins were quantified by
autoradiography.ican Journal of Human Genetics 93, 211–223, August 8, 2013 215
Immunoblotting
Supernatants from the 600 3 g centrifugation step of tissue ho-
mogenates contain different amounts of mitochondrial proteins.
Based on previous immunoblots decorated with porin antibody,
the amount of crude mitochondrial extract was adjusted to yield
equal amounts of mitochondrial protein by loading 4–10 mg of
protein. Samples were loaded on AnykD precast gels (BioRad)
and separated for 30 min at 150 V. Blotting was performed with
the Trans Blot Turbo for Nitrocellulose Mini Format (BioRad)
and the MixedMW transfer protocol (BioRad). Immunostaining
was performed as described previously12 with NDUFS4 (1/
1,000; ab55540), SDHA (1/30,000; ab14715), UQCRC2 (1/2,000;
ab14745), MTCO1 (1/1,000; ab14705), ATP5A (1/1,000;
ab14748), and porin (1/1,000; ab14734) (all from Abcam) anti-
bodies overnight at 4C. As secondary antibody, the HRP-labeled
EnVisionþ Polymer anti mouse (DAKO) was diluted 1/100 and
incubated for 1 hr at room temperature.
For immunoblot analysis from fibroblasts, 8 mg of total cell
lysates were subjected to SDS-PAGE, transferred to nitrocellulose
membrane, blocked in 5% nonfat milk in PBS for 1 hr, and incu-
bated with specific primary antibodies overnight. The blots were
further incubated with HRP-conjugated secondary antibodies for
1 hr and visualized with ECLþ (Amersham). Primary antibodies
(anti-complex I subunit NDUFB8, anti-complex II subunit
30 kDa, anti-complex III subunit core 2, anti-complex IV subunit
II) were purchased from Abcam.RNA Isolation and RNA Blotting
RNA isolation and RNA blotting was performed essentially as
described previously.13 In brief, total RNA from fibroblasts of
subject #57415 (F1: II-3) was isolated with Trizol (Invitrogen)
according to the manufacturer’s instructions. RNA was resolved
on 1% agarose gels containing 0.7 M formaldehyde in 13 MOPS
buffer, transferred to a nylonmembrane in 23 SSC, and hybridized
with either radioactively labeled PCR fragments corresponding to
appropriate regions of mtDNA (to detect mt-mRNAs) or T7 RNA
polymerase-transcribed radioactive RNA fragments complemen-
tary to particular mt-tRNAs. Detailed sequence information on
the probes used for RNA blotting can be found in Tables S3 and S4.Results
Exome Sequencing Identifies ELAC2 Mutations
We performed exome sequencing to elucidate the molecu-
lar basis of the disease in individuals #57415 and #61982
(F1: II-3 and F2: II-5 in Figure 1A). Exonic regions were
enriched with the SureSelect Human All Exon 50 Mb kit
(Agilent) and sequenced as 100 base-pair (bp) paired-end
runs on a HiSeq2000 (Illumina) to an average 1103
and 1523 coverage with >93% of the target being
covered >203. For sequencing statistics see Table S1.
We detected a total of ~11,000 single-nucleotide variants
(SNVs) and small insertions and deletions (indels) per indi-
vidual. To prioritize the likely disease-causing mutations,
we applied filters accounting for the very rare and severe
mitochondrial disease phenotype and an assumed reces-
sive model of inheritance. We first excluded variants pre-
sent with a frequency >0.2% in 1,846 control exomes
and public databases, which left 277 (#57415, F1: II-3)216 The American Journal of Human Genetics 93, 211–223, August 8and 529 (#61982, F2: II-5) rare variants. We next searched
for genes carrying either homozygous variants or two or
more different heterozygous variants in the same gene
and identified 9 and 67 candidates in individuals #57415
(F1: II-3) and #61982 (F2: II-5), respectively. However, in
both affected individuals, only one gene, ELAC2, encoded
a protein with a predicted mitochondrial localization
(MitoP2 score > 0.5) according to the MitoP2 database.9
Individual #61982 (F2: II-5) carries a homozygous
missense mutation, c.460T>C (p.Phe154Leu), affecting
an amino acid residue conserved from human to fruit fly
and worm (Figure 1B) with deleterious consequences as
predicted in silico.14,15
Individual #57415 (F1: II-3) harbors a stop mutation,
c.631C>T (p.Arg211*), compound heterozygous with a
missense mutation, c.1559C>T (p.Thr520Ile), changing
an amino acid conserved also in Saccharomyces cerevisiae
with predicted pathogenic consequences. The affected
sibling (#61525; F1: II-2) carries both mutations whereas
the healthy parents are heterozygous carriers for onemuta-
tion each with c.631C>T being present on the maternal
and c.1559C>T on the paternal allele. The healthy
sister is a heterozygous carrier of the c.631C>T mutation
(F1: II-1).
We next screened 350 individuals with OXPHOS disor-
ders for genetic variation in ELAC2 and identified a homo-
zygous missense mutation, c.1267C>T (p.Leu423Phe), in
two affected siblings (#36355 and #65937; F3: II-1 and
II-2) from a third family.
Together, the identification of four different alleles
(Figure 1B) in five affected individuals from three families
with a similar phenotype provides strong evidence for a
disease-causing role of mutant ELAC2 in recessively
inherited mitochondrial disease.Unprocessed mtRNA Precursors Are Increased in
Mutant Muscle and Fibroblasts
To directly analyze the levels of unprocessed mt-tRNAs
resulting from impaired RNase Z activity in affected indi-
vidual’s tissues, we first used a quantitative real-time PCR
(qPCR) approach. We therefore designed primers flanking
ten ELAC2 processing sites located directly upstream of
mt-mRNA and mt-rRNA genes (Figure 2A). With these
primers, we were able to specifically amplify unprocessed
mt-tRNA-mRNA or mt-tRNA-rRNA junctions for all tRNAs
tested in control muscle tissue and fibroblasts. The analysis
of skeletal muscle samples available from individuals
#57415 and #65937 (F1: II-3 and F3: II-2) revealed a
dramatic increase in precursor levels of up to 400-fold
compared to control muscle samples (Figure 2B). In
contrast to skeletal muscle, the effect of the ELAC2 muta-
tions in fibroblasts (#57415, #61982, and #65937; F1:
II-3, F2: II-5, and F3: II-2) was less pronounced, but signif-
icant with up to 30-fold increased levels of mtRNA pre-
cursors in eight out of ten processing sites in all samples
(Figure 2C)., 2013
A B
C
#57415  / p.[Arg211*; Thr520Ile]
#65937 / p.[Leu423Phe; Leu423Phe] 
p.[Arg211*; Thr520Ile] p.[Phe154Leu; Phe154Leu] p.[Leu423Phe; Leu423Phe] 
ELAC2 WT
Figure 2. Quantification and Rescue of the Mitochondrial mRNA Processing Defect by qPCR
(A) Map of the mitochondrial genome with the annotation of rRNA, tRNA, and mRNA genes among the heavy and light strand.
Numbering 1–10 indicates the RNA cleavage sites located 50 terminal of rRNAs or mRNAs. As an example for the primer design, a scheme
of the tRNAArg-ND4L junction is given.
(B and C) Quantification of the ten unprocessed mitochondrial tRNA-rRNA or tRNA-mRNA junctions analyzed by qPCR in (C) muscle
and (D) fibroblasts before () and after (þ) transduction with a wild-type ELAC2 expression construct. Values are given as fold change to
the average of three different controls. Error bars indicate51 standard deviation (SD) from the mean of at least three technical (B) or
biological (C) replicates.mt-tRNA Processing Defect Is Rescued in Mutant
Fibroblasts by Exogenous ELAC2
In order to verify that the observed defect in 30 end
mt-tRNA processing was due to mutations in ELAC2,
we performed cDNA complementation experiments.
Lentiviral-mediated expression of ELAC2 cDNA in fibro-
blasts from individuals #57415, #61982, and #65937 (F1:
II-3, F2: II-5, and F3: II-2) resulted in a normalization of
unprocessed mt-tRNA precursors demonstrating the rescue
of the mt-tRNA processing defect (Figure 2). These resultsThe Amerimply that impaired RNase Z activity in mutant ELAC2 is
responsible for the mt-tRNA processing defect in all three
individuals.
Mitochondrial Transcriptome in ELAC2 Mutant
Individuals
The detected processing defect suggested a possible effect
on mature mt-tRNA levels. We therefore investigated the
levels of 14 mt-tRNAs by RNA blotting of total RNA iso-
lated from fibroblasts of individual #57415 (F1: II-3). Weican Journal of Human Genetics 93, 211–223, August 8, 2013 217
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Figure 3. Steady-State Levels Mitochondrial RNAs and RNA-Seq in Mutant Fibroblasts
(A and B) Quantification of steady-state levels of (A) 14 mt-tRNAs and (B) 3 mt-mRNAs and 16S mt-rRNA in control and affected
individual’s (#57415) fibroblasts by RNA blot analysis. 18S rRNA was used as loading control.
(C) Mitochondrial transcriptome analysis by next-generation sequencing (RNA-seq) of fibroblasts RNA from ELAC2 individuals and
three controls. Relative sequencing coverage is plotted against the mitochondrial genome (numbering according to RefSeq accession
(legend continued on next page)
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did not find a decrease in the steady-state levels in any of
the mt-tRNA species investigated as compared to controls,
and apparent increased levels of some mt-tRNAs were
observed (Figure 3A). Additional single-nucleotide resolu-
tion RNA blots showed the mitochondrial tRNALeu(UUR)
and tRNASer(AGY) to be of the same length in mutant and
control fibroblasts, consistent with both containing a
CCA tail (Figure S1).
Because 30 end cleavage of intervening mt-tRNAs is also
crucial for the maturation of the adjacent mt-mRNAs or
mt-rRNAs, we next quantified mitochondrial mRNAs and
16S-rRNA levels. However, despite the detected defect in
the processing of the 30 end of mt-tRNAs, RNA blotting
did not show any considerable changes in the steady-state
levels the four mtRNAs analyzed (Figure 3B).
In order to gain further insights into the properties of
mtRNA of the ELAC2 mutant individuals, we sequenced
the transcriptome (RNA-seq) derived from all three
individuals and three control fibroblasts. Altogether,
mitochondrial transcripts represented about 4% of all
sequenced transcripts. Because of their small size and the
lack of poly(A) tail, mt-tRNAs were not captured for
sequencing. The lack of polyadenylation in mt-rRNAs
resulted in some degree of depletion of these species, so
that the mt-rRNA levels obtained in the RNA-seq analysis
do not represent the physiological ones. The coverage of
sequenced positions of mitochondrial transcripts was on
average 4,850-fold and reached 18,000-fold maximally,
interspersed with regions of virtually no coverage for mt-
tRNAs (Figure 3C). The number of sequence reads for
each mitochondrial transcript did not vary significantly
between the analyzed ELAC2mutant and control cell lines.
This result confirms the RNA blotting data in that there
were no substantial differences in the steady-state levels
of both mt-rRNAs and all the mt-mRNAs between affected
individual and control samples. However, the RNA-seq
allowed for comprehensive analysis of processing of
the 30 and 50 termini of all mt-mRNAs and mt-rRNAs
(Figure 3C). As expected, we found no evidence of per-
turbed 30 end processing of mt-mRNAs or mt-rRNAs.
Also, the processing at the sites that are not punctuated
by mt-tRNA (e.g., ATP8/6-MT-COIII) was not affected in
the affected individual’s samples as compared to the
controls. However, concordant with our qPCR results, we
found significantly increased amounts of 50 end unpro-
cessed mt-mRNA and mt-rRNA precursors at several cleav-
age sites that are preceded by a mt-tRNA as compared to
the control cell lines (Figure 3C). The defect in the process-
ing of mt-tRNA/mt-mRNA junctions was confirmed by
RNA blotting for selected species (Figure 3D).
Together, these results suggest that impaired 30 end pro-
cessing of mt-tRNAs does not essentially reduce steady-number J01415). Colored lines represent individuals #57415 (
line indicates the average of three controls. The ten RNase Z clea
magnification.
(D) RNA blot analysis decorated with tRNALeu(UUR)- and tRNAVal-spec
The Amerstate levels of mature mt-tRNAs or other mitochondrial
transcripts, but leads to the accumulation of a substantial
fraction of unprocessed mt-tRNA-RNA molecules among
the mt-mRNAs.
ELAC2 Mutations Impair Mitochondrial Translation
We next tested whether the defect in mtRNA processing
resulting from reduced RNase Z activity of mutant ELAC2
affects mitochondrial translation. Fibroblasts from indi-
vidual #57415 (F1: II-3) had a reduced rate of synthesis of
mtDNA-encoded OXPHOS components as shown by
quantification of 35S-labeled methionine in the presence
of emetine, an inhibitor of cytosolic translation (Figures
4A and 4B). This correlated with reduced steady-state levels
of OXPHOS proteins as assayed by immunoblotting of
total protein fractions from fibroblasts (Figure 4C). An
impairedmitochondrial protein synthesis and/or assembly
of respiratory chain complex I was also suggested by
immunoblot analysis of OXPHOS levels in muscle from
individual #57415 (F1: II-3), whereas complex II (which
contains only nuclear encoded subunits) was found to be
increased (Figure 4D). Together, these findings suggest a
defect in translation of mtDNA-encoded proteins in
ELAC2 mutant tissues. These data imply a disease model
whereby defective processing of precursor mtRNA exerts
its effects neither via reduced levels of mature mt-tRNAs
nor mt-mRNAs or mt-rRNAs but might be associated
with an accumulation of processing intermediates
hampering effective mitochondrial translation.
Rescue Experiments in Yeast Substantiate
Pathogenicity of the Thr520Ile Mutation
To further substantiate the pathogenicity of identified
ELAC2mutations, we studied the p.Thr520Ile substitution
conserved in yeast corresponding to the change Thr513Ile
in the essential RNase Z ortholog Trz1 (Figure S2A). By
using the plasmid shufflingmethod,16 we generated a dele-
tion strain expressing either the trz1 mutant or the TRZ1
wild-type allele. In the trz1 mutant strains, we observed a
typical phenotype indicative of impaired respiratory chain
function,17 a reduced growth rate on medium containing
nonfermentable carbon sources (Figure S2B). Direct testing
of overall respiration rate and COX activity showed a 40%
decrease in both parameters as compared to the TRZ1
wild-type strain (Figures S2C and S2D). Assessment ofmito-
chondrial translation by [35S]methionine labeling in the
presence of cycloheximide demonstrated a clear reduction
in the rate of synthesis of all mtDNA-encoded gene prod-
ucts (Figure S2E). Furthermore, we observed a higher petite
frequency, a finding that in yeast typically occurs when
mitochondrial translation is quantitatively reduced (Fig-
ure S2F). In summary, these data confirm that the Thr520Ileblue), #61982 (red), and #65937 (green). The black dotted
vage sites analyzed by qPCR (Figure 2) are shown with higher
ific probes to detect unprocessed mt-tRNA-mRNA intermediates.
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Figure 4. Mitochondrial Translation and
Steady-State Levels of Respiratory Chain
Complexes in Mutant Fibroblasts
(A and B) Analysis of mitochondrial
translation products in fibroblasts from in-
dividual #57415 by [35S]methionine pulse
labeling (A) and quantification of three
experiments (B). Error bars indicate 51
SD from the mean of three replicates.
mtDNA-encoded structural subunits of
complex I (ND1, ND2, ND3, ND4, ND4L,
ND5, ND6), complex III (cytb), complex
IV (MT-COI, MT-COII, MT-COIII), and
complex V (ATP6, ATP8) are shown.
(C and D) Immunoblot analysis of respira-
tory chain complex subunits in crude
mitochondrial extractions from individual
#57415 and control (C) fibroblasts as well
as (D) muscle. Porin antibody was used as
a loading control in muscle.substitution in ELAC2 causes defective mitochondrial
respiration via impaired mitochondrial translation.Discussion
Here, we describe five individuals with a severe, infancy-
onset disorder and mutations in ELAC2, which has origi-
nally been reported as a susceptibility gene for heritable
prostate cancer (MIM 614731). Despite a study question-
ing the functional consequences of cancer-associated
missense variants,18 two of them, p.Ser217Leu and
p.Ala541Thr, have been reinforced as low-penetrance
susceptibility markers of prostate cancer by a recent
meta-analysis.19 Alongside a potential role in tumorgene-
sis, ELAC2 has been shown to interact with gamma-
tubulin complexes in the cytoplasm20 and the RNAi
knockdown of the Caenorhabditis elegans ortholog to
interfere with germline proliferation.21 Impaired mt-
tRNA (or nuclear tRNA) processing may also contribute
to the pathogenesis of prostate cancer; however, here we
demonstrate that impaired RNase Z activity of ELAC2
causes a fatal failure in cellular energy metabolism.
OXPHOS disorders usually present with vast allelic
heterogeneity and a broad spectrum of clinical manifesta-
tions, hindering attempts to establish clear genotype-220 The American Journal of Human Genetics 93, 211–223, August 8, 2013phenotype correlations. Although
the severity and course of the disease
differs among the five ELAC2 mutant
individuals, it is important to high-
light several consistent features.
Hypertrophic cardiomyopathy is a
potentially life-limiting key clinical
feature and has been documented
in all individuals before the age of
6 months. Two genetically con-
firmed cases bearing the alterations
p.[Arg211*; Thr520Ile] (#61525; F1:II-2) and p.[Phe154Leu; Phe154Leu] (#61982; F2: II-5) died
within thefirst yearof life due to cardiac failure, andanother
two siblings of #61982 (F2: II-5) with unclear genetic
status but suggestive clinical presentations died before the
age of 3 months. In individuals with the substitution
p.[Leu423Phe; Leu423Phe] (#36355 and #65937; F3: II-1
and II-2), despite intense anticongestive therapy, cardiomy-
opathy progressed toward a dilated form by the age of
4 years, leading to death in one of them within 1 year.
In four out of five affected individuals, a mild to marked
developmental delay has been documented.
Neuroimaging studies documented hyperintensities in
T2-weighted MRI in the pallida in one individual with the
substitutions p.[Arg211*; Thr520Ile] (#57415; F1: II-3);
another individual, #36355 (F3: II-1), had normal scans.
Laboratory investigations consistently showed elevated
lactate levels in blood together with associated elevations
of amino acids (alanine, glutamine) in serum. Analysis of
mitochondrial respiratory chain enzymes from muscle
revealed a complex I defect in all affected individuals,
suggesting that complex I deficiencymight be themost sen-
sitive indicator for mitochondrial dysfunction. However,
the defect was mild in some and associated with a complex
IV deficiency in individual #36355 (F3: II-1). In addition,
numerous COX-deficient fibers were detected in case
#65937 (F3: II-2) although not in all affected individuals.
C
C
A
 mRNA
wild-type ELAC2
 mRNA AAAAAAAAAAA 5`
Translation
Correct 3` end
 processing
Aberrent 3` end
 processing
RNA 
surveillance
mutation in ELAC2
Aberrent 3` end
 processing
C
C
A
 mRNA
 mRNA AAAAAAAAAAA 5`
Translation
Correct 3` end
 processing RNA 
surveillance
Figure 5. Model of Potential ELAC2 Path-
omechanism
Suggested model of normal and impaired
ELAC2 activity. Under normal conditions
minor amounts of unprocessed ELAC2
substrates can be degraded by the RNA sur-
veillance machinery. Reduced ELAC2
activity results in an accumulation ofmito-
chondrial precursor mRNAs, which impair
mitochondrial translation.We provide several lines of evidence arguing for a dis-
ease-causing role of ELAC2 mutations including (1) statis-
tical evidence by identifying four disease alleles in three
families with a similar biochemical and clinical pheno-
type, (2) functional evidence by documentation of
elevated 30 end unprocessed tRNA levels in tissues of
affected individuals that were corrected upon lentiviral
expression of wild-type ELAC2 cDNA, and (3) confirma-
tion of the deleterious consequences of the missense muta-
tion Thr520Ile by modeling in yeast. So far only mtDNA
mutations have been implicated in tRNA processing de-
fects.22 The present study establishes nuclear mutations
as a cause of a human disease affecting mitochondrial
RNA processing.
A role of ELAC2 in mt-tRNA processing has been deter-
mined previously and was now confirmed by our study.
The analysis of respiratory chain complex activities in
mutant skeletal muscle demonstrated a significant
OXPHOS defect, which resulted in a severe, infancy-onset
disorder. Our experiments in fibroblast cell lines derived
from affected individuals indicate that ELAC2 is crucial
for efficient synthesis of mtDNA-encoded proteins and
proper steady-state levels of structural OXPHOS compo-
nents, consistent with respiratory chain defects detected
in affected individual’s skeletal muscle. Proper function of
ELAC2 is more important in skeletal muscle than in fibro-
blast cell cultures, probably reflecting different needs
and thresholds for mitochondrial expression of respiratory
chain complexes.23 A previous ELAC2 RNAi knockdown
study in HeLa cells suggested that mitochondrial transla-
tion and OXPHOS activity remained unaffected.7 These
divergent results may be explained by the difference of
transient or persistent ELAC2 inactivation. Although
RNAi can sufficiently reduce ELAC2 and leads to accumu-
latedmtRNA precursors at the time of subsequent analyses,
the exposure to these changes might be too short to
manifest downstream effects, e.g., impaired mitochondrial
translation. Another variable is the difference in the cell
types analyzed, highlighting the importance of establish-
ing cell lines from affected individuals, which are valuable
resources for the functionalwork-up inmetabolic disorders.
What are the mechanisms connecting impaired mito-
chondrial processing and altered mitochondrial transla-
tion? Mutations in several mt-tRNAs have been shown
to hamper 30 end processing and to cause defective mito-The Amerchondrial respiration.22,24,25 For example, a number of
disease-linked mutations in the mt-tRNA(LeuUUR) gene
(e.g., m.3243A>G, m.3271T>C, and m.3302A>G) show
reduced steady-state levels of this mt-tRNA in vivo, associ-
ated with an increase in corresponding precursors.26
Further in vitro experiments demonstrated that these
base substitutions in mt-tRNA(LeuUUR) interfere with 30
end processing.27 Also, pathological mutations in the
T-loop of mt-tRNA(Ile) and mt-tRNA(Gly) (m.4317A>G
and m.10044A>G, respectively) result in impaired bind-
ing of substrate mt-tRNA to the 30 processing enzyme
and inhibition of CCA addition to the respective tRNA
by the human mitochondrial CCA-adding enzyme.25,28
In these cases, the mt-tRNA levels or aminoacylation
became the limiting factor for mitochondrial protein syn-
thesis. However, in contrast to prior studies suggesting
decreased levels of mature mt-tRNAs upon ELAC2
silencing, our investigations demonstrate normal levels
of mt-tRNAs and no defect in maturation. Our results
argue against decreased mt-tRNA levels as the limiting
factor for translation resulting from impaired ELAC2 func-
tion and shifted our focus to investigate mt-mRNA
processing. The concomitant maturation of mt-mRNAs
by 30 end mt-tRNA processing is a key issue, because
mammalian mitochondrial 55S ribosomes preferentially
form initiation complexes at a 50-terminal AUG over an
internal AUG, and it is questionable whether unprocessed
mt-mRNA can be translated at all.29 The latter finding
suggests that unprocessed precursor mt-mRNAs are not
efficiently translated. Based on the 400-fold increase in
50 end unprocessed mt-mRNAs in affected individuals
muscle tissue, the most direct explanation for an
OXPHOS defect would be diminished levels of mature
mt-mRNAs (Figure 5, in black). However, our results
from RNA-seq experiments argue that a maximum of
10% of the mt-mRNAs are unprocessed at the 50 end in
mutant fibroblasts and such a minor fraction should be
tolerated by the cell. Because of the limited availability
of muscle tissue from affected individuals, we could not
determine the ratio of processed to unprocessed mt-
tRNA-mRNA junctions. The near 400-fold increase in
the levels of mtRNA precursors observed in affected indi-
viduals muscle samples (compared to controls) could be
considered sufficient to decrease the proportion of func-
tional mt-mRNA molecules to the extent that translationican Journal of Human Genetics 93, 211–223, August 8, 2013 221
is significantly impaired. Nonetheless, the observed defect
in mutant fibroblasts, despite practically normal levels of
matured mt-tRNA, mt-mRNA, and mt-rRNA, led us to pro-
pose an additional model in which the accumulation of
aberrantly processed mtRNA species that fail to be elimi-
nated by the RNA surveillance machinery might interfere
with translation (Figure 5, in red).
In conclusion, we have used exome sequencing to iden-
tify ELAC2mutations as the molecular genetic correlate of
OXPHOS deficiency associated with infantile-onset hyper-
trophic cardiomyopathy, encephalopathy, and lactic
acidosis. In line with an RNase Z function of ELAC2 in
mitochondria, we have shown that mitochondrial RNA
precursors accumulate in affected individuals fibroblasts
and skeletal muscle. We established in ELAC2 mutant cell
lines and yeast that ELAC2 and its yeast ortholog TRZ1
are crucial for efficient mitochondrial translation and
function. This study highlights an important role for
next-generation sequencing approaches in the investiga-
tive diagnostic algorithm for individuals with suspected
mitochondrial disease because they not only reliably iden-
tify known disease mutations and genes but can also reveal
fundamental insights into the underlying cell biology and
pathomechanisms.Supplemental Data
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